Introduction
============

Marfan syndrome (MFS) is a multisystemic disorder of connective tissue inherited in an autosomal dominant fashion[@B1]. It is caused by mutations in the extracellular matrix protein fibrillin 1[@B2]. Current diagnostic manifestations include skeletal, ocular, cardiovascular, pulmonary, cutaneous, and central nervous system abnormalities as well as a family history[@B3][@B4]. There have been numerous case reports of MFS in infancy; however, infantile MFS is still rarely diagnosed at younger ages, because morphological characteristics of the syndrome are age-dependent, phenotypic variability is remarkable, and most patients show *de novo* mutations[@B3]. Cardiovascular abnormalities are the major cause of death in infantile MFS, and the most common presenting findings are mitral and/or tricuspid valve regurgitation, which is less common in classic MFS[@B5][@B6]. Long-term follow-up and proper management including open-heart surgery in a timely manner would have beneficial effects on the prognosis of the patients. However, little is known about infantile MFS in South Korea. The aim of this study was to evaluate cardiovascular manifestations and the overall prognosis of recently diagnosed cases of infantile MFS in a tertiary referral center in South Korea.

Materials and methods
=====================

Between 2004 and 2014, among the 180 patients who had been followed up for MFS during this period, eight patients were clinically diagnosed with infantile MFS at Seoul National University Hospital. Diagnosis of MFS was based on the revised Ghent criteria[@B4][@B7]. Systemic score is one of the diagnostic criteria and is calculated according to the most selective systemic features and the score greater than or equal to 7 points was considered a positive systemic score[@B4]. All available medical records were reviewed retrospectively, including gender, birth weight and height, age at diagnosis, follow-up duration, other systemic involvement, family history, echocardiographic findings, gene testing, operations, medications, and mortality. This study was approved by the Institutional Review Boards of Seoul National University Hospital (IRB number: H-1501-016-636), and informed consent was waived because of its retrospective nature.

Results
=======

1. Demographic findings
-----------------------

[Table 1](#T1){ref-type="table"} shows the demographic data of 8 patients (2 boys and 6 girls) with infantile MFS. Five patients had medical records reporting height at birth, and the median was 50.0 cm (range, 48--53 cm). Among these 5 patients, only one patient was taller than the 90th percentile of height at birth. Their ages at the time of diagnosis ranged from 0 to 20 months (median age, 2.5 months) and the median follow-up duration was 25.5 months (range, 0--94 months). The most common presenting symptom was a heart murmur, in three patients, and one patient was diagnosed *in utero*. At the time of this study, four of the 8 patients were taller than the 95th percentile of height.

Three of the patients (cases 1, 2, and 4) were lost to follow-up at our hospital. By asking other hospital physicians and the statistical service of the Ministry of Government Administration and Home Affairs, we learned that two of these patients died during follow-up at other hospitals and one patient is still alive. Among the 5 patients who were followed up at our hospital, 3 patients are still alive, but the other 2 died during follow-up. One patient (case 3) died from heart failure despite several operations, including mitral valve replacement (MVR). This patient was referred to our hospital for myocarditis but she was diagnosed with decompensated heart failure due to mitral valve chordae rupture from MFS. The other patient (case 8) died from heart failure 3 days after birth despite intensive inotropic support. The median age of mortality was 12 months (range, 0--131 months).

All patients had no family history of MFS; however, MFS was suspected in the mother of one patient, though we did not perform genetic confirmation for this mother ([Table 2](#T2){ref-type="table"}). Among the eight patients, ophthalmic examination was performed on five, and three of these had lens subluxation. We performed a fibrillin 1 (*FBN1*) gene mutation test in 5 patients, and 4 of these were identified as having a *FBN1* gene mutation. There was only 1 patient whose systemic score of Ghent nosology was greater or equal to 7 points. Dilatation of the aortic sinus diameter is defined as a *z* score greater than 2[@B8]. One patient did not have echocardiographic records of aortic sinus diameter, and the *z* score of the other seven patients was greater than 2, with a median z value of 5.46 (range, 3.87--7.57).

2. Cardiovascular manifestations and treatment
----------------------------------------------

All patients had mitral valve prolapse (MVP) and the z score of the mitral valve annulus in five of the seven patients who had accurate measurements of mitral valve annulus size was greater than 2 ([Table 3](#T3){ref-type="table"}). All patients had various degrees of mitral regurgitation (MR) at initial echocardiography. The MR was mild in 2 patients, moderate in 2 patients, and severe in 4 patients at the time of diagnosis.

Other than 1 patient who had no medical record of tricuspid valve findings from echocardiography, all of the patients had tricuspid valve prolapse. Only 3 patients had an echocardiographic record of the tricuspid valve annulus diameter and the *z* score was less than 2. All eight patients had various degrees of tricuspid regurgitation (TR). The TR was mild in 3 patients, moderate in 4 patients, and severe in 1 patient.

Six patients had medical records of aortic annulus diameter and all of them had an aortic annulus z score greater than 2. Six patients had aortic regurgitation (AR), and the AR was trivial in 3 patients, mild in 2 patients, and moderate in 1 patient. No patients had severe AR. There were seven patients with congestive heart failure before surgery or during follow-up.

Five patients underwent open-heart surgery, and MVR was performed in all cases at the median age of 28.5 months (range, 5--69 months). Among them, 2 patients needed multiple operations. One of these patients underwent MVR at a 4-year-old, a David operation at a 5.7-year-old, and aortic valve replacement at an 8.9-year-old. The other patient underwent mitral valve repair and tricuspid valve annuloplasty at the age of 3 months, and MVR at the age of 5 months. All patients except for the one who died at 3 days of age took multiple medications, including losartan and atenolol. The patients with congestive heart failure were also prescribed diuretics and digoxin.

Discussion
==========

In our series of 8 cases of infantile MFS, most patients showed significant atrioventricular valve dysfunction and resulting congestive heart failure symptoms. Five patients required early MVR for heart failure symptoms. The prognosis of infantile MFS is very grave and half of infantile MFS patients showed mortality at the median age of 12 months in our series.

MFS is a systemic disorder of connective tissue. The prevalence of MFS has been estimated to be approximately 1--2 per 10,000 individuals without gender or ethnic differences; however, the true incidence is difficult to determine because the manifestations of the disease become more obvious with age[@B1][@B9][@B10].

A 5-year-old child who had congenital contractures, long extremities, and spider-like digits was first described by French pediatrician Antoine Marfan in 1896[@B11]. Later, involvements of the ocular and cardiovascular system were noted and the first diagnostic criteria for the disorder were established in 1988 (Berlin nosology)[@B12]. Currently, the diagnosis relies on features of the skeletal, ocular, cardiovascular, cutaneous, central nervous, and pulmonary systems in addition to family history and *FBN1* mutations[@B4][@B7].

Infantile or neonatal MFS is rarely diagnosed and is a type of MFS that is atypical and has a severe effect on the cardiovascular system[@B13]. In older or classic MFS, cardiovascular events leading to death are mostly aortic dissection or ruptures; however, deaths among neonatal MFS patients are associated with CHF due to MR or TR[@B14]. In addition, infantile MFS has higher mortality rate within the first year of life than classic MFS of which the mean age at death is 33.5 years of life[@B15][@B16]. It is considered to usually be caused by a new mutation, not because of a positive family history[@B15]. In our 8 patients, all patients had no definitive family history. One patient had suspected mother, but she had never been diagnosed with MFS.

Even though infantile MFS is rare and difficult to diagnose, there are clues as to whether a newborn has infantile MFS. If fetal ultrasound reveals cardiomegaly and marked valvular lesions, fetal echocardiography should be performed and cautiously examined for both, atrioventricular prolapse and aortic root dilatation[@B17]. In addition to the fetal echocardiography, length at birth can be a useful tool to evaluate infantile MFS. Erkula et al.[@B18] reported that the mean height at birth in MFS patients approached the 90th percentile of the general population in both males and females, suggesting that excessive growth in MFS patients begins prenatally. However, among the 5 patients for whom we found height at birth data in our series, only 1 patient showed greater than 90 percentile of height. Congenital emphysema is also common in neonatal MFS and the syndrome can be suspected when a neonate presents pulmonary emphysema with typical manifestations[@B5][@B19][@B20]. A characteristic phenotype of affected infants includes an aged face, arachnodactyly, dolichocephaly, high-arched palate, micrognathia, joint hyperflexibility, joint contractures, pes planus, and chest deformity, as seen in our patients[@B3] ([Figs. 1](#F1){ref-type="fig"},[2](#F2){ref-type="fig"},[3](#F3){ref-type="fig"}).

The prognosis of infantile MFS diagnosed during the first year of life is known to be poor. The life span of infantile MFS patients is expected to be less than 2 years because of the severity of the cardiovascular problems[@B15]. The majority of these patients require both medical and surgical management, and the available medical and surgical strategies for patients with MFS are directed towards prevention of cardiovascular complications[@B21]. Beta blocking agents are currently recommended for early use by MFS patients[@B22]. In pediatric MFS patients, beta blockers are known to delay cardiac interventions. However, in infant MFS patients, the benefits of using beta blocker are not known[@B3][@B23][@B24]. Infants with MFS who have atrioventricular valve insufficiencies usually require digoxin and/or diuretics to prevent congestive heart failure; this was similar to the requirement in our patients. In spite of using multiple medications, valve surgery is generally necessary because moderate or severe MR associated with left ventricular volume overload provokes congestive heart failure and may lead to sudden cardiac death[@B22]. Both mitral valve repair and/or replacement can be an option for surgical treatment; however, the outcome data on valve surgery are limited in patients with infantile MFS. Furthermore, there is a high probability of mortality and morbidity including complete heart block, thrombosis, and stroke after valve surgery[@B25][@B26][@B27]. In our study, three patients died despite MVR.

Because of potential new therapies and proper explanation to the parents, it is increasingly important to recognize infantile MFS prenatally in addition to shortly after birth in order to perform diagnostic work-up and initiate appropriate management in a timely fashion[@B28].

In conclusion, because the prognosis of infantile MFS is very grave, early detection and a timely cautious treatment is essential to prevent further morbidity and mortality.
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![Case 7. (A) Loose skin and arachnodactyly. (B, C) Arachnodactyly of the hand and foot at 14 days of age.](kjped-59-59-g002){#F2}
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###### Clinical findings of the patients with infantile Marfan syndrome

![](kjped-59-59-i001)

  Case   Sex   At birth        At diagnosis   Presenting symptom   Follow-up period (mo)            At the time of study   Mortality                                    
  ------ ----- --------------- -------------- -------------------- -------------------------------- ---------------------- ----------- --------------- ---------------- ---------
  1      F     3.48 (50--75)   NA             12                   Cannot stand up alone at 12 mo   94                     130         32.5 (25--50)   159.6 (\>97)     Expired
  2      F     2.5 (\<3)       NA             8                    Murmur                           39                     47          12.6 (\<3)      88.5 (10--25)    Alive
  3      F     3.35 (50--75)   51 (50--75)    0                    Murmur                           17                     20          7.3 (\<3)       86.6 (75--90)    Expired
  4      F     3.7 (75--90)    NA             2                    NA                               0                      4           6.5 (25--50)    69.2 (\>97)      Expired
  5      M     3.09 (25--50)   50(25--50)     20                   Myopia                           44                     100         23.7 (10--25)   135.7 (75--90)   Alive
  6      F     2.9 (10--25)    49 (25--50)    3                    Murmur                           34                     38          14.5 (50--75)   111 (\>97)       Alive
  7      M     3.31 (25--50)   53 (90--95)    0                    Desaturation at birth            5                      5           7.6 (25--50)    72.1 (95--97)    Alive
  8      F     2.56 (3--5)     48 (25--50)    0                    Prenatal US                      0                      0           2.7 (5--10)     48 (25--50)      Expired

NA, not available; US, ultrasonography.

###### Revised Ghent nosology pattern in each of the patients with infantile Marfan syndrome
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  Case   Family history   Aorta (*z*≥3)    Ectopia lentis   *FBN1* gene mutation   Systemic score
  ------ ---------------- ---------------- ---------------- ---------------------- ----------------
  1      Negative         35.4 mm (6.10)   NA               NA                     6
  2      Negative         NA               --               NA                     NA
  3      Negative         31.0 mm (7.57)   \+               --                     6
  4      Negative         20.9 mm (5.02)   NA               \+                     3
  5      Negative         32.4 mm (5.46)   \+               \+                     13
  6      Negative         25.1 mm (6.37)   \+               \+                     6
  7      Negative         16.5 mm (4.66)   --               \+                     2
  8      Negative         13.8 mm (3.87)   NA               NA                     4

NA, not available; *FBN1*, Fibrillin 1.

###### Cardiovascular complications and treatment of each of the patients with infantile Marfan syndrome

![](kjped-59-59-i003)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   MVP   MV annulus, mm (*z* score)   MR         TVP   TV annulus, mm (*z* score)   TR         Aortic annulus, mm (*z* score)   AR         CHF       Op.                                         Age at Op.                         Medications at last follow-up
  ------ ----- ---------------------------- ---------- ----- ---------------------------- ---------- -------------------------------- ---------- --------- ------------------------------------------- ---------------------------------- -------------------------------
  1      \+    39.5 (4.10)                  Severe     \+    NA                           Mild       24.2 (5.96)                      Moderate   Present   1\. MVR\                                    1.48 mo\                           SRN, CTP, DGX, CVD, FRS, WFR
                                                                                                                                                           2. Valve-sparing aortic root replacement\   2.5 yr 8 mo\                       
                                                                                                                                                           3. AVR                                      3.8 yr 10 mo                       

  2      \+    NA                           Severe     NA    NA                           Moderate   NA                               Mild       Present   \-                                          \-                                 ENL, DGX

  3      \+    30 (5.14)                    Severe           NA                           Moderate   NA                               Trace      Present   1\. MV repair, TV annuloplasty\             1.3 mo\                            DGX, FRS, SRN, LST, WFR, ENL
                                                                                                                                                           2. MVR\                                     2.5 mo\                            
                                                                                                                                                           3. Bilateral lensectomy\                    3.8 mo\                            
                                                                                                                                                           4. Lung volume reduction                    4.16 mo                            

  4      \+    25.7 (3.76)                  Severe     \+    22.5 (1.81)                  Moderate   13.6 (4.50)                      None       Present   MVR                                         Less than 1 yr at other hospital   LST, FRS, SRN, PRN

  5      \+    37.4 (3.84)                  Moderate   \+    NA                           Mild       19.9 (4.19)                      Trace      Present   MVR                                         69 mo                              WFR, ATN, LST

  6      \+    29.3 (4.42)                  Moderate   \+    NA                           Mild       13.6 (4.13)                      None       Present   MVR                                         9 mo                               WFR, ATN, LST

  7      \+    14.8 (1.30)                  Mild       \+    12.8 (-0.22)                 Moderate   9 (2.46)                         Trace      None      \-                                          \-                                 ATN

  8      \+    13.9 (1.47)                  Mild       \+    17.3 (1.82)                  Severe     8.7 (3.10)                       Mild       Present   \-                                          \-                                 Inotropics
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MV, mitral valve; MVP, mitral valve prolapse; MR, mitral regurgitation; TVP, tricuspid valve prolapse; TV, tricuspid valve; TR, tricuspid regurgitation; AR, aortic regurgitation; CHF, congestive heart failure; Op., operation; NA, not available; MVR, mitral valve replacement; AVR, aortic valve replacement; SRN, spironolactone; CTP, captopril; DGX, digoxin; CVD, carvedilol; FRS, furosemide; WFR, warfarin; ENL, enalapril; LST, losartan; PRN, propranolol; ATN, atenolol.
